[Skip to Content]
[Skip to Content Landing]
Citations 0
Health Agencies Update
October 26, 2011

Blood Clot Risk

JAMA. 2011;306(16):1750. doi:10.1001/jama.2011.1538

Oral contraceptives containing drospirenone may be associated with a higher risk of venous thromboembolism (VTE) than birth control pills without this ingredient, according to a US Food and Drug Administration (FDA) safety update.

The FDA issued the update in late September to alert the public that preliminary results from an agency study found a 1.5-fold increase in VTE among women taking oral contraceptives containing drospirenone compared with users of other hormonal contraceptives (http://www.fda.gov/Drugs/DrugSafety/ucm273021.htm). Previously, the agency had announced it was evaluating conflicting data on whether a higher risk of VTE was associated with drospirenone use compared with use of birth control pills containing levonorgestrel or other progestins.

First Page Preview View Large
First page PDF preview
First page PDF preview